|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/13/17 Idt Corp 10-Q 1/31/17 68:3.8M Edgar Agents LLC/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 382K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 23K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 23K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 19K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 19K
12: R1 Document and Entity Information HTML 39K
13: R2 Consolidated Balance Sheets HTML 125K
14: R3 Consolidated Balance Sheets (Parenthetical) HTML 42K
15: R4 Consolidated Statements of Income (Unaudited) HTML 80K
16: R5 Consolidated Statements of Comprehensive Income HTML 44K
(Unaudited)
17: R6 Consolidated Statements of Cash Flows (Unaudited) HTML 117K
18: R7 Basis of Presentation HTML 24K
19: R8 Zedge Spin-Off HTML 31K
20: R9 Investment in Cornerstone Pharmaceuticals, Inc. HTML 30K
21: R10 Marketable Securities HTML 59K
22: R11 Fair Value Measurements HTML 40K
23: R12 Derivative Instruments HTML 35K
24: R13 Equity HTML 47K
25: R14 Earnings Per Share HTML 36K
26: R15 Revolving Credit Loan Payable HTML 24K
27: R16 Accrued Severance Expense HTML 21K
28: R17 Accumulated Other Comprehensive Loss HTML 32K
29: R18 Business Segment Information HTML 51K
30: R19 Commitments and Contingencies HTML 41K
31: R20 Other (Expense) Income, Net HTML 28K
32: R21 Income Taxes HTML 23K
33: R22 Recently Issued Accounting Standard Not Yet HTML 32K
Adopted
34: R23 Zedge Spin-Off (Tables) HTML 26K
35: R24 Marketable Securities (Tables) HTML 87K
36: R25 Fair Value Measurements (Tables) HTML 36K
37: R26 Derivative Instruments (Tables) HTML 25K
38: R27 Equity (Tables) HTML 40K
39: R28 Earnings Per Share (Tables) HTML 45K
40: R29 Accumulated Other Comprehensive Loss (Tables) HTML 27K
41: R30 Business Segment Information (Tables) HTML 60K
42: R31 Commitments and Contingencies (Tables) HTML 28K
43: R32 Other (Expense) Income, Net (Tables) HTML 31K
44: R33 Zedge Spin-Off (Details) HTML 27K
45: R34 Investment in Cornerstone Pharmaceuticals, Inc. HTML 87K
(Details)
46: R35 Marketable Securities (Details) HTML 64K
47: R36 Marketable Securities (Details 1) HTML 34K
48: R37 Marketable Securities (Details 2) HTML 44K
49: R38 Marketable Securities (Details Textual) HTML 38K
50: R39 Fair Value Measurements (Details) HTML 30K
51: R40 Fair Value Measurements (Details Textual) HTML 22K
52: R41 Derivative Instruments (Details) HTML 21K
53: R42 Equity (Details) HTML 62K
54: R43 Equity (Details Textual) HTML 60K
55: R44 Earnings Per Share (Details) HTML 33K
56: R45 Earnings Per Share (Details 1) HTML 22K
57: R46 Revolving Credit Loan Payable (Details) HTML 46K
58: R47 Accrued Severance Expense (Details) HTML 26K
59: R48 Accumulated Other Comprehensive Loss (Details) HTML 48K
60: R49 Business Segment Information (Details) HTML 42K
61: R50 Business Segment Information (Details Textual) HTML 20K
62: R51 Commitments and Contingencies (Details) HTML 28K
63: R52 Commitments and Contingencies (Details Textual) HTML 40K
64: R53 Other (Expense) Income, Net (Details) HTML 33K
65: R54 Income Taxes (Details) HTML 24K
67: XML IDEA XML File -- Filing Summary XML 117K
66: EXCEL IDEA Workbook of Financial Reports XLSX 61K
6: EX-101.INS XBRL Instance -- idt-20170131 XML 1.04M
8: EX-101.CAL XBRL Calculations -- idt-20170131_cal XML 137K
9: EX-101.DEF XBRL Definitions -- idt-20170131_def XML 382K
10: EX-101.LAB XBRL Labels -- idt-20170131_lab XML 931K
11: EX-101.PRE XBRL Presentations -- idt-20170131_pre XML 600K
7: EX-101.SCH XBRL Schema -- idt-20170131 XSD 127K
68: ZIP XBRL Zipped Folder -- 0001213900-17-002245-xbrl Zip 100K
EXHIBIT 31.1
CERTIFICATION
OF CHIEF EXECUTIVE OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Shmuel Jonas, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of IDT Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this Report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| Date: March 13, 2017 | /s/ Shmuel Jonas |
Shmuel Jonas Chief Executive Officer |
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/13/17 | None on these Dates | ||
| For Period end: | 1/31/17 | |||
| List all Filings | ||||